



Media release

European Patent Office issues Notice of Decision to Grant European Patent

Melbourne Australia 3 February 2020: Invictus BioPharma Ltd, the Company commercialising an innovative new non-invasive and direct drug and vitamin delivery platform which eliminates the use of needles, says the European Patent Office has issued a Notice of Decision to Grant a patent for the transmucosal delivery of tocotrienols.

The patent covers transmucosal delivery of tocotrienols for promoting the treatment or prevention of post exercise muscle soreness, delayed onset muscle soreness, and improving exercise endurance and performance. Patent claims are also directed at reducing inflammation, cardiac fibrosis and treatment of cancer amongst other claims.

This patent formally entitled 'Transmucosal Delivery of Tocotrienol' will provide commercial rights in up to 38 European member states of the European Patent Office until 13 November 2033.

Invictus BioPharma Ltd Executive Chairman and Chief Executive Officer Dr Glenn Tong said "The grant of the EU patent is another positive step forward in the global commercialisation of the Company's nutraceutical products which have wide consumer appeal and prescription medicines addressing medical conditions of high unmet need.

"Europe is a significant market for nutraceuticals and pharmaceuticals and patent coverage there strengthens Invictus BioPharma's ability to commercialise both its nutraceutical and prescription medicine products," he said.

Invictus BioPharma has corresponding patents granted in Australia, New Zealand, Singapore, South Africa, Japan and patent applications are pending in other major markets including the US where an *ex parte* Quayle motion has been issued and Invictus expects this patent application to be granted in the near future.

For more information please contact:

Dr Glenn Tong
Invictus BioPharma Ltd.
Tel: 0412 193 350

About Invictus BioPharma Ltd.

Invictus BioPharma Ltd. is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. Invictus BioPharma owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: www.invictusbiopharma.com